Clinical Trial Update: Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating SON-1010 in combination with atezolizumab for platinum-resistant ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• SON-1010

Snippet

Sponsor: Sonnet BioTherapeutics | Conditions: Advanced Solid Tumor, Platinum-resistant Ovarian Cancer | Phase 1, Phase 2 | Status: TERMINATED